Clinical trials: Cardiac Events
Hypercholesterolemia
A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
The purpose of this study is to investigate the effect of an investigational cholesterol-lowering drug in patients who are currently taking an approved medication for hypercholesterolemia (high cholesterol levels) and have been…
- Trial name
- NCT00132717
- Testing
- MK0653A (ezetimibe [+] simvastatin), Comparator: atorvastatin, Comparator: fluvastatin
- Volunteers
- 450 people
- Sponsor
- Organon and Co
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Heart Failure
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
The aim of this study is to develop and validate an improved, comprehensive risk assessment algorithm integrating blood RNA-based biomarkers, clinical, and patient-centered data and to assess the incremental predictive value…
- Trial name
- ORACLE (NCT05679713)
- Testing
- Comprehensive risk assessment algorithm
- Where
- Spain
- Volunteers
- 1,134 people
- Sponsor
- Hospital Universitari de Bellvitge
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily (od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation therapy with a lower risk of bleeding in…
- Trial name
- NCT00243178
- Testing
- clopidogrel (SR25990C)
- Where
- 32 sites in United States, Australia and 30 more
- Volunteers
- 6,706 people
- Sponsor
- Sanofi
Atrial Fibrillation
Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)
This trial will include patients who have a heart condition called atrial fibrillation. Atrial fibrillation is an abnormal rhythm (irregular beat) in the heart.
- Trial name
- NCT00070655
- Testing
- SR34006 (idraparinux sodium) Injection, vitamin K antagonist (warfarin or acenocoumarol) tablets
- Where
- 84 sites in United States, Australia and 8 more
- Volunteers
- 4,673 people
- Sponsor
- Sanofi
Major Adverse Cardiac Event (MACE)
How Clinical and Personal Information Shape Physicians' Risk Judgments
Physicians often form quick judgments about the risk for serious disease when interacting with patients. Underestimating risk can lead to underuse of diagnostic testing and untreated illness, which can worsen patient outcomes.
- Trial name
- NCT07162376
- Testing
- Personal Information Disclosure
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Coronary Artery Disease, Therapeutics
PEACE Prospective Study of Patients With Three-vessel Disease
Coronary heart disease (CHD) pose a serious health threaten to population. Optimal revascularization strategy in multiple vessel coronary artery disease patients remains a subject of debate between interventional cardiologists…
- Conditions
- Coronary Artery Disease, Therapeutics, Outcome Assessment
- Trial name
- PEACE3VD (NCT01617785)
- Where
- China
- Volunteers
- 4,500 people
- Sponsor
- China National Center for Cardiovascular Diseases
Acute Kidney Injury, Critical Illness
Predicting Adverse Kidney Events of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers
The aim of this study was to identify and validate novel biomarkers for predict acute kidney injury (AKI) subphenotype, major adverse kidney events and other poor outcomes.
- Conditions
- Acute Kidney Injury, Critical Illness, Kidney Failure
- Trial name
- NCT06351813
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Shanghai Zhongshan Hospital
Angioplasty, Transluminal, Percutaneous Coronary
Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention
The purpose of this study is to investigate the effect of cilostazol loading before planned PCI on major adverse cardiac and cerebrovascular events in patients with coronary artery disease.
- Trial name
- PRECEDE (NCT00938522)
- Testing
- Cilostazol
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Samsung Medical Center
Ventricular Tachycardia, Premature Ventricular Contraction
DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
The purpose of this study is to learn if taking a drug called direct oral anticoagulant after an ablation procedure keeps blood clots from forming and lowers the chance of having a stroke in patients with ventricular tachycardia…
- Conditions
- Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
- Trial name
- STROKE-VT (NCT02666742)
- Testing
- DOAC, Aspirin
- Where
- 5 sites in United States, India
- Volunteers
- 246 people
- Sponsor
- Kansas City Heart Rhythm Institute
Binge Drinking
Afferent Neurocardiac Signals, Cue Reactivity, and Cognitive Control
Conscious attempts to regulate alcohol use are often undermined by automatic attention and arousal processes activated by alcohol cues, as well as by diminished ability to inhibit in-the-moment behaviors.
- Trial name
- NCT05369169
- Testing
- Resonance breathing, Low demand cognitive task
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Postpartum Depression (PPD), Cardiac Event
Living Healthy for Moms RCT
LHMoms is a novel integrated care intervention that focuses intensively on care continuity and community-to-healthcare linkages for postpartum birthing individuals.
- Trial name
- LHMoms (NCT06666400)
- Testing
- LHMoms Intervention, No intervention
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Columbia University
Atherosclerotic Cardiovascular Disease
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Primary Objective: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and…
- Trial name
- NCT01663402
- Testing
- Alirocumab, LMT
- Where
- 1,388 sites in United States, Argentina and 55 more
- Volunteers
- 18,924 people
- Sponsor
- Sanofi
Chest Wall Tumor, Breast Cancer
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Radiation therapy is an essential treatment for tumors in the chest area, including breast, lung, esophageal, mediastinal cancers, and spine metastases.
- Conditions
- Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- NCT07685938
- Testing
- Atorvastatin and Lisinopril
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Myocardial Infarction
Effects of Early Statin Treatment After Acute Myocardial Infarction (AMI) in Japanese Patients
Statins have been shown to prevent coronary artery disease and to preserve left ventricular function in dilated cardiomyopathy. The investigators hypothesized that the early use of statins would reduce cardiovascular events…
- Trial name
- NCT00128024
- Testing
- lipid-lowering treatment
- Where
- Japan
- Volunteers
- 460 people
- Sponsor
- Kumamoto University
Cardiac Disease, Cancer
Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)
Antineoplastic and immunomodulating agents may lead to various cardio-vascular adverse reactions. This study investigates reports of cardio-vascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC)…
- Trial name
- EROCA (NCT03530215)
- Testing
- Antineoplastic and Immunomodulating Agents
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Preoperative Care, Surgery--Complications
Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study
The proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting.
- Conditions
- Preoperative Care, Surgery--Complications, Myocardial Infarction
- Trial name
- VALIANCE (NCT04973397)
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Heart Failure
Telemonitoring and Teleintervention of Heart Failure and Decrease of Non-fatal Events.
The primary objective of the study is to determine the effect of automated daily selfreported symptom and weight, blood pressure and heart rate monitoring and clinical follow-up videoconference comigrate with clinical follow-up…
- Trial name
- ICOR (NCT01495078)
- Testing
- Telemonitoring
- Where
- Spain
- Volunteers
- 178 people
- Sponsor
- Parc de Salut Mar
Atrial Fibrillation, Stroke, Acute
Characterization and Prediction of Atrial Fibrillation-caused Adverse Events After Hospital Discharge for Cardiac Surgery
The purpose of the research is to identify the frequency and severity of adverse events related to atrial fibrillation that occur after discharge from hospital where the patient underwent cardiac surgery.
- Conditions
- Atrial Fibrillation, Stroke, Acute, Death
- Trial name
- MATRICeS (NCT03466125)
- Testing
- Cardiac surgery
- Where
- United States
- Volunteers
- 25,000 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice.
- Trial name
- NCT01152606
- Testing
- trastuzumab [Herceptin]
- Where
- 205 sites in Austria, Belgium and 7 more
- Volunteers
- 3,942 people
- Sponsor
- Hoffmann-La Roche